U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Best Practices in Developing Proprietary Names for Drugs
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Best Practices in Developing Proprietary Names for Drugs May 2014

Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2014-D-0622
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

FDA is issuing this guidance to help sponsors of human drugs, including those that are biological products, develop proprietary names2 that do not cause or contribute to medication errors or otherwise contribute to the misbranding of the drug. This guidance describes design practices to help avoid such errors with proprietary names and provides a qualitative systematic framework for evaluating proposed proprietary names before submitting them for FDA review. This guidance does not address the selection of established names or proper names.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-0622.

Back to Top